Events
What’s New at the J.P. Morgan Life Healthcare Conference?
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
After almost 25 years and more than 70 successful euroPLX Pharma Partnering Conferences which are attended by Business Development Executives from 86 countries worldwide, RauCon is now expanding this unique concept to Asia in order to better serve the company’s Asian customers.
Madrid, January 9th, 2020- PharmaMar management will be meeting with institutional investors in San Francisco during the JP Morgan Annual Healthcare Conference next week.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
Predicine and Merck KGaA, Darmstadt, Germany collaboratively highlight the importance of multi-parametric profiling of ctDNA and cfRNA for holistic molecular insight for detecting driver mutation, monitoring disease burden and drug resistance in advanced stage colorectal cancer.
Atriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January.
Selonterra, Inc., a biotechnology company discovering transformative therapies for neurodegenerative disorders by harnessing human genetics and gene regulatory networks announced a presentation at the Biotech Showcase™ 2020 to be held January 13–15 at the Hilton San Francisco Union Square.
$4.5 million awarded to six outstanding early career scientists to support innovation in cancer research
Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019.
PRESS RELEASES